Literature DB >> 9025713

Altered blood pressure profile, autonomic neuropathy and nephropathy in insulin-dependent diabetic patients.

P T Monteagudo1, J C Nóbrega, P R Cezarini, S R Ferreira, O Kohlmann, A B Ribeiro, M T Zanella.   

Abstract

To evaluate the relationship between autonomic neuropathy (AN) and nephropathy we measured 24-h blood pressure (BP) and overnight urinary albumin excretion (UAE) in 38 patients with insulin dependent diabetes mellitus (IDDM). Autonomic function was evaluated by the heart rate response to deep breathing. Valsalva maneuver, heart rate at rest and BP variation with posture. Sympathetic cutaneous reflex was also tested in both inferior and superior limbs. Patients with mean day diastolic BP (DDBP) < or = 90 mmHg without AN (N = 15) compared to 12 normal controls had similar BP values, but compared to those with DDBP < or = 90 mmHg and AN (N = 12) they had lower night diastolic BP (NDBP) (66 +/- 4.8 vs 72 +/- 8.8 mmHg: p < 0.05) and UAE (9.8 +/- 2.3 vs 107.2 +/- 3.5 micrograms/min; p < 0.001). No difference in DDBP was observed between these two diabetic groups (80 +/- 3.9 vs 83 +/- 6.1 mmHg). Of the 11 patients with DDBP > 90 mmHg, only three were free of AN and only two of the eight with AN where free of diabetic nephropathy. The percentage day/night changes in systolic BP were lower in patients with AN (13 vs 7.9%; p < 0.05) and were inversely related to autonomic score, used as an index of the degree of autonomic dysfunction (r = -0.48; p < 0.01) and to UAE (r = -0.39; p < 0.05). Furthermore, UAE correlated with autonomic score (r = 0.69; p < 0.0001) and with NDBP (r = 0.44; p < 0.01). Our results show that AN in IDDM patients is associated with a reduced nocturnal fall in BP and suggest a pathogenic role of autonomic dysfunction in the development of diabetic nephropathy, possibly favoring both BP elevation during the night and increases in intraglomerular pressure.

Entities:  

Mesh:

Year:  1996        PMID: 9025713     DOI: 10.1530/eje.0.1350683

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

Review 1.  The Role of Circadian Rhythms in the Hypertension of Diabetes Mellitus and the Metabolic Syndrome.

Authors:  Björn Lemmer; Henrik Oster
Journal:  Curr Hypertens Rep       Date:  2018-05-05       Impact factor: 5.369

2.  Nocturnal antihypertensive treatment in patients with type 1 diabetes with autonomic neuropathy and non-dipping of blood pressure during night time: protocol for a randomised, placebo-controlled, double-blind, two-way crossover study.

Authors:  Henrik Hjortkær; Tonny Jensen; Klaus Kofoed; Ulrik Mogensen; Lars Køber; Karen Lisa Hilsted; Helle Corinth; Simone Theilade; Jannik Hilsted
Journal:  BMJ Open       Date:  2014-10-07       Impact factor: 2.692

3.  The longevity gene mIndy (I'm Not Dead, Yet) affects blood pressure through sympathoadrenal mechanisms.

Authors:  Diana M Willmes; Martin Daniels; Anica Kurzbach; Stefanie Lieske; Nicole Bechmann; Tina Schumann; Christine Henke; Nermeen N El-Agroudy; Andrey C Da Costa Goncalves; Mirko Peitzsch; Anja Hofmann; Waldemar Kanczkowski; Kristin Kräker; Dominik N Müller; Henning Morawietz; Andreas Deussen; Michael Wagner; Ali El-Armouche; Stephen L Helfand; Stephan R Bornstein; Rafael de Cabo; Michel Bernier; Graeme Eisenhofer; Jens Tank; Jens Jordan; Andreas L Birkenfeld
Journal:  JCI Insight       Date:  2021-01-25

4.  Cardiac Autonomic Dysfunction Is Associated With Risk of Diabetic Kidney Disease Progression in Type 2 Diabetes Mellitus.

Authors:  Haixia Zeng; Jianmo Liu; Zheng Chen; Peng Yu; Jianping Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-01       Impact factor: 6.055

5.  Blood pressure variability and its association with echocardiographic parameters in hypertensive diabetic patients.

Authors:  Daniela Massierer; Liana Farias Leiria; Mateus Dorneles Severo; Priscila Dos Santos Ledur; Alexandre Dalpiaz Becker; Fernanda Mus Aguiar; Eliandra Lima; Valéria Centeno Freitas; Beatriz D Schaan; Miguel Gus
Journal:  BMC Cardiovasc Disord       Date:  2016-01-08       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.